Evidence map›Paper›PMID 38494553›Full record

ArticleAnnals of hematology2024

Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia.

Xiao-Tong Huang, Chan-Juan Wang, Chao Gao, Tian-Lin Xue, Zi-Jing Zhao, Tian-You Wang, Min-Yuan Wu, Lei Cui, Rui-Dong Zhang, Zhi-Gang Li

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xiao-Tong HuangHematologic Diseases Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Chan-Juan WangNational Key Discipline of Pediatrics, Capital Medical University, Beijing, China.
Chao GaoHematologic Diseases Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Tian-Lin XueHematologic Diseases Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Zi-Jing ZhaoHematologic Diseases Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Tian-You WangNational Key Discipline of Pediatrics, Capital Medical University, Beijing, China.
Min-Yuan WuNational Key Discipline of Pediatrics, Capital Medical University, Beijing, China.
Lei CuiHematologic Diseases Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. cuileilsh@163.com.
Rui-Dong ZhangNational Key Discipline of Pediatrics, Capital Medical University, Beijing, China. zhangruidong@vip.sina.com.
Zhi-Gang LiHematologic Diseases Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Ericlzg70@hotmail.com.
Capital Medical University · CNBeijing Children’s Hospital · CN

Funding

the Beijing Natural Science Foundation of China No. 7202044the National Natural Science Foundation of China No. 81870114the National Natural Science Foundation of China No. 81970135the New Sunshine Charity Foundation, China No. 2017002
6 · The paper itself

Abstract

Minimal residual disease (MRD) based risk stratification criteria for specific genetic subtypes remained unclear in childhood acute lymphoblastic leukemia (ALL). Among 723 children with newly diagnosed ALL treated with the Chinese Children Leukemia Group CCLG-2008 protocol, MRD was assessed at time point 1 (TP1, at the end of induction) and TP2 (before consolidation treatment) and the MRD levels significantly differed in patients with different fusion genes or immunophenotypes (P all < 0.001). Moreover, the prognostic impact of MRD varied by distinct molecular subtypes. We stratified patients in each molecular subtype into two MRD groups based on the results. For patients carrying BCR::ABL1 or KMT2A rearrangements, we classified patients with MRD < 10

Indexed as

Neoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantMaleOncogene Proteins, FusionPrognosisOncogene Proteins, FusionALLFusion geneMRDRelapseRisk stratification

Identifiers

PMID38494553
OpenAlexW4393095147

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.